Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Cash from Financing Activities (2017 - 2023)

Rapid Therapeutic Science Laboratories' Cash from Financing Activities history spans 7 years, with the latest figure at -$8087.0 for Q2 2023.

  • For Q2 2023, Cash from Financing Activities fell 102.42% year-over-year to -$8087.0; the TTM value through Jun 2023 reached $140952.0, down 94.51%, while the annual FY2022 figure was $998380.0, 54.52% down from the prior year.
  • Cash from Financing Activities for Q2 2023 was -$8087.0 at Rapid Therapeutic Science Laboratories, down from $59386.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.7 million in Q3 2021 and bottomed at -$8087.0 in Q2 2023.
  • The 5-year median for Cash from Financing Activities is $230000.0 (2021), against an average of $359011.9.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 4614.29% in 2020 before it tumbled 102.42% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $300000.0 in 2019, then skyrocketed by 357.33% to $1.4 million in 2020, then rose by 20.99% to $1.7 million in 2021, then tumbled by 97.81% to $36403.0 in 2022, then tumbled by 122.22% to -$8087.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Cash from Financing Activities are -$8087.0 (Q2 2023), $59386.0 (Q1 2023), and $36403.0 (Q4 2022).